It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Since the 2019 novel coronavirus disease (COVID-19) outbreak originated from Wuhan, Hubei Province, China, at the end of 2019, it has become a clinical threat to the general population worldwide. Among people infected with the novel coronavirus (2019-nCoV), the intensive management of the critically ill patients in intensive care unit (ICU) needs substantial medical resource. In the present article, we have summarized the promising drugs, adjunctive agents, respiratory supportive strategies, as well as circulation management, multiple organ function monitoring and appropriate nutritional strategies for the treatment of COVID-19 in the ICU based on the previous experience of treating other viral infections and influenza. These treatments are referable before the vaccine and specific drugs are available for COVID-19.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Shanghai Jiao Tong University School of Medicine, Department of Critical Care Medicine, Ruijin Hospital, Shanghai, People’s Republic of China (GRID:grid.16821.3c) (ISNI:0000 0004 0368 8293)
2 Huadong Hospital Affiliated to Fudan University, Department of Surgical Intensive Care Unit, Shanghai, People’s Republic of China (GRID:grid.413597.d) (ISNI:0000 0004 1757 8802)
3 Zhejiang Provincial People’s Hospital, Department of Critical Care Medicine, Hangzhou, People’s Republic of China (GRID:grid.417401.7) (ISNI:0000 0004 1798 6507)
4 The First Hospital Affiliated to Harbin Medical University, Department of Critical Care Medicine, Harbin, People’s Republic of China (GRID:grid.410736.7) (ISNI:0000 0001 2204 9268)
5 Shanghai Jiao Tong University School of Medicine, Department of Critical Care Medicine, Ruijin North Hospital, Shanghai, People’s Republic of China (GRID:grid.16821.3c) (ISNI:0000 0004 0368 8293)
6 Shanghai Jiao Tong University School of Medicine, Department of Critical Care Medicine, Ruijin Hospital, Shanghai, People’s Republic of China (GRID:grid.16821.3c) (ISNI:0000 0004 0368 8293); Shanghai Jiao Tong University School of Medicine, Department of Critical Care Medicine, Ruijin North Hospital, Shanghai, People’s Republic of China (GRID:grid.16821.3c) (ISNI:0000 0004 0368 8293)